TITLE

18-month occurrence of severe events among early diagnosed HIV-infected children before antiretroviral therapy in Abidjan, Côte d'Ivoire: a cohort study

AUTHOR(S)
Harambat, Jérôme; Fassinou, Patricia; Becquet, Renaud; Touré, Pety; Rouet, François; Dabis, François; Msellati, Philippe; Blanche, Stéphane; Timité-Konan, Marguerite; Salamon, Roger; Leroy, Valériane
PUB. DATE
January 2008
SOURCE
BMC Public Health;2008, Vol. 8 Issue 1, p169
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective: To assess the 18-month field effectiveness on severe events of a pediatric package combining early HIV-diagnosis and targeted cotrimoxazole prophylaxis in HIV-infected children from age six-week before the antiretroviral era, in Abidjan, Côte d'Ivoire. Methods: Data from two consecutive prevention of HIV mother-to-child transmission programs were compared: the ANRS 1201/1202 Ditrame-Plus cohort (2001-2005) and the pooled data of the ANRS 049a Ditrame randomized trial and its following open-labeled cohort (1995-2000), used as a reference group. HIV-infected pregnant women ⩾ 32-36 weeks of gestation were offered a short-course peri-partum antiretroviral prophylaxis (ZDV in Ditrame, and ZDV ± 3TC+singledose (sd) NVP in Ditrame-Plus). Neonatal prophylaxis was provided in Ditrame-Plus only: 7-day ZDV and sdNVP 48-72 h after birth. A 6-week pediatric HIV-RNA diagnosis was provided on-line in the Ditrame-Plus while it was only oriented on clinical symptoms in Ditrame. Six-week HIV-infected children received a daily cotrimoxazole prophylaxis in Ditrame-Plus while no prophylaxis was provided in Ditrame. The determinants of severe events (death or hospitalization > 1 day) were assessed in a Cox regression model. Results: Between 1995 and 2003, 98 out of the 1121 live-births were diagnosed as HIV-infected in peri-partum: 45 from Ditrame-Plus and 53 from Ditrame. The 18-month Kaplan-Meier cumulative probability of presenting a severe event was 66% in Ditrame-Plus (95% confidence interval [95%CI]: 50%-81%) and 77% in Ditrame (95%CI: 65%-89%), Log Rank test: p = 0.47. After adjustment on maternal WHO clinical stage, maternal death, 6-week pediatric viral load, birth-weight, and breastfeeding exposure, the 18-month risk of severe event was lower in Ditrame-Plus than in Ditrame (adjusted Hazard Ratio (aHR): 0.55, 95%CI: 0.3-1.1), although the difference was not statistically significant; p = 0.07). Maternal death was the only variable determinant of the occurrence of severe events in children (aHR: 3.73; CI: 2.2-11.2; p = 0.01). Conclusion: Early cotrimoxazole from 6 weeks of age in HIV-infected infants seemed to reduce probability of severe events but the study lacked statistical power to prove this. Even with systematic cotrimoxazole prophylaxis, infant morbidity and mortality remained high pointing towards a need for early pediatric HIV-diagnosis and antiretroviral treatment in Africa.
ACCESSION #
51485758

 

Related Articles

  • Severe morbidity and mortality in untreated HIV-infected children in a paediatric care programme in Abidjan, Côte d'Ivoire, 2004-2009. Desmonde, Sophie; Coffie, Patrick; Aka, Edmond; Amani-Bosse, Clarisse; Messou, Eugène; Dabis, François; Alioum, Ahmadou; Ciaranello, Andrea; Leroy, Valériane // BMC Infectious Diseases;2011, Vol. 11 Issue 1, p182 

    Background: Clinical evolution of HIV-infected children who have not yet initiated antiretroviral treatment (ART) is poorly understood in Africa. We describe severe morbidity and mortality of untreated HIV-infected children. Methods: All HIV-infected children enrolled from 2004-2009 in a...

  • Improved Growth and Anemia in HIV-Infected African Children Taking Cotrimoxazole Prophylaxis. Prendergast, Andrew; Walker, A. Sarah; Mulenga, Veronica; Chintu, Chifumbe; Gibb, Diana M. // Clinical Infectious Diseases;Apr2011, Vol. 52 Issue 7, p953 

    The impact of cotrimoxazole (CTX) on growth and/or anemia was investigated in 541 human immunodeficiency virus-infected, antiretroviral therapy–naive Zambian children enrolled in the Children with HIV Antibiotic Prophylaxis trial. Compared with children randomized to receive placebo,...

  • Early ART may achieve 'functional cure' in children with HIV. Galella, Matthew; Richards, Cassandra A.; Stott, Robert // Infectious Diseases in Children;Apr2013, Vol. 26 Issue 4, p13 

    The article discusses a research study which revealed that early application of antiretroviral therapy may achieve cure in HIV-positive children, presented at the Conference on Retroviruses and Opportunistic Infections in Atlanta, Georgia on March 3 to 6, 2013.

  • Feasibility and effectiveness of combination antiretroviral therapy in HIV-infected infants in Pietermaritzburg, South Africa. Van der Linden, D.; Purchase, S.; McKerrow, N. H. // Journal of the International AIDS Society;2010 Supplement 4, Vol. 13 Issue Suppl 4, p1 

    An abstract of the article "Feasibility and effectiveness of combination antiretroviral therapy in HIV-infected infants in Pietermaritzburg, South Africa," by several authors including DVan der Linden, S Purchase, and NH McKerrow is presented.

  • Successful paediatric HIV treatment in rural primary care in Africa. Janssen, N.; Ndirangu, J.; Newell, M.-L.; Bland, R. M. // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Jun2010, Vol. 95 Issue 6, p4 

    Objective Clinical outcomes of HIV-infected children on antiretroviral treatment (ART) in a decentralised, nurse/counsellor-led programme. Design Clinical cohort. Setting KwaZulu-Natal, South Africa. Patients HIV-infected children aged =15 years on ART, June 2004-2008. Main outcome measures...

  • Profile of HIV Infected Children from Delhi and Their Response to Antiretroviral Treatment. GOMBER, SUNIL; KAUSHIK, JAYA SHANKAR; CHANDRA, JAGDISH; ANAND, RAHUL // Indian Pediatrics;Sep2011, Vol. 48 Issue 9, p703 

    Objectives: (i) To study the clinical and immunological profile of HIV infected children attending the ART centre; (ii) To correlate CD4 count with clinical staging at diagnosis; and, iii) To study the clinical and immunological response to antiretroviral treatment. Setting: Antiretroviral...

  • Swift treatment helps tots with HIV.  // New Scientist;8/31/2013, Vol. 219 Issue 2932, p17 

    The article discusses research begun in 2005 by Mark Cotton of Stellenbosch University in Cape Town, South Africa in a 2013 issue of the journal "The Lancet" that found early anti-retroviral drug treatment of HIV-positive infants lowered their risk of dying early in childhood.

  • HIV transmitted drug resistance in adult and pediatric populations in Panama. Castillo, Juan; Arteaga, Griselda; Mendoza, Yaxelis; Martínez, Alexander A.; Samaniego, Rigoberto; Estripeaut, Dora; Page, Kathleen R.; Smith, Rebecca E.; Sosa, Nestor; Pascale, Juan M. // Pan American Journal of Public Health;Dec2011, Vol. 30 Issue 6, p649 

    Objective. To investigate the prevalence of transmitted drug-resistant HIV among adults in Panama by using a modified World Health Organization Threshold Survey (WHO-TS) and to investigate rates of initial resistance among HIV-positive infants in Panama. Methods. At the Gorgas Memorial...

  • Usefulness of a genotypic resistance test using dried blood spot specimens in African HIV-infected children with virological failure according to the 2010-revised WHO criteria. Charpentier, Charlotte; Gody, Jean-Chrysostome; Tisserand, Pascaline; Matta, Mathieu; Fournier, Julien; Mbitikon, Olivia; Bélec, Laurent // Archives of Virology;Sep2011, Vol. 156 Issue 9, p1603 

    We compared paired plasma and dried blood spot (DBS) samples from 54 HIV-1-treated children living in Bangui, Central African Republic, for antiretroviral-resistance-associated mutations. All children displayed virological failure (HIV-1 RNA >3.70 logcopies/ml). Testing for resistance genotype...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics